D3 Bio (wuxi) Co., Ltd
Clinical trials sponsored by D3 Bio (wuxi) Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New pill targets Hard-to-Treat cancer mutation Results expected Apr 2027 (estimated)
-
New pill targets Hard-to-Treat cancer mutation in early human test
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called D3S-003 in 42 people with advanced solid tumors that have a specific genetic change called KRAS G12D. The main goals are to check the drug's safety, find the right dose, and see how the body processes it. Particip…
Phase 1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancers with MAPK gene flaw
Disease control Recruiting nowThis early-phase trial tests an experimental drug called D3S-002, taken as a daily pill, in adults with advanced solid tumors that have MAPK pathway mutations. The study has two parts: first, finding a safe dose, and second, testing that dose alone or with another drug (D3S-001) …
Phase 1/2 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Sep 06, 2026 00:00 UTC
-
New hope for HER2 cancers? early trial of D3L-001 begins
Disease control Recruiting nowThis early-phase trial is testing a new drug called D3L-001 in 128 people with advanced HER2-positive solid tumors. The main goals are to check the drug's safety, find the right dose, and see early signs of whether it can shrink tumors. Participants receive D3L-001 through an IV,…
Phase 1 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New pill targets Hard-to-Treat cancer mutation
Disease control Recruiting nowThis study tests a new oral drug called D3S-001, alone or with other cancer drugs, in people with advanced solid tumors that have a specific KRAS G12C mutation. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 442 participants will …
Phase 1/2 • Sponsor: D3 Bio (Wuxi) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC